open access

Vol 9, No 4 (2023)
Review paper
Published online: 2023-09-27
Get Citation

The potential role of Helicobacter pylori and other gut dysbiosis factors in the development of rosacea

Zuzanna Luiza Frydrych1, Natalia Chwarścianek1, Karolina Błaszak1, Rafał Czajkowski1
·
Forum Dermatologicum 2023;9(4):138-142.
Affiliations
  1. Department of Dermatology and Venerology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland

open access

Vol 9, No 4 (2023)
REVIEW ARTICLES
Published online: 2023-09-27

Abstract

Rosacea is a chronic inflammatory disease that presents with erythema, telangiectasia, papules, or pustules. Its mechanism of onset stillneeds to be fully understood. There has been an increasing number of studies and reports confirming the beneficial influence of eradicationof Helicobacter pylori on the course of the disease. It has been recognized that the bacterium leads to the activation of the inflammatoryimmune response, resulting in the induction of symptoms similar to rosacea. Another thesis suggests a close connection between thegut–brain–skin axis, which relates to the influence of normal microbiota and gut health, and dermatological diseases. Correlations havebeen noted between the increased incidence of Crohn’s disease, ulcerative colitis, and irritable bowel syndrome in patients with rosacea.

Abstract

Rosacea is a chronic inflammatory disease that presents with erythema, telangiectasia, papules, or pustules. Its mechanism of onset stillneeds to be fully understood. There has been an increasing number of studies and reports confirming the beneficial influence of eradicationof Helicobacter pylori on the course of the disease. It has been recognized that the bacterium leads to the activation of the inflammatoryimmune response, resulting in the induction of symptoms similar to rosacea. Another thesis suggests a close connection between thegut–brain–skin axis, which relates to the influence of normal microbiota and gut health, and dermatological diseases. Correlations havebeen noted between the increased incidence of Crohn’s disease, ulcerative colitis, and irritable bowel syndrome in patients with rosacea.

Get Citation

Keywords

rosacea, Helicobacter pylori, eradication, microbiota

About this article
Title

The potential role of Helicobacter pylori and other gut dysbiosis factors in the development of rosacea

Journal

Forum Dermatologicum

Issue

Vol 9, No 4 (2023)

Article type

Review paper

Pages

138-142

Published online

2023-09-27

Page views

476

Article views/downloads

296

DOI

10.5603/fd.96224

Bibliographic record

Forum Dermatologicum 2023;9(4):138-142.

Keywords

rosacea
Helicobacter pylori
eradication
microbiota

Authors

Zuzanna Luiza Frydrych
Natalia Chwarścianek
Karolina Błaszak
Rafał Czajkowski

References (41)
  1. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002; 46(4): 584–587.
  2. Alexis AF, Callender VD, Baldwin HE, et al. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: review and clinical practice experience. J Am Acad Dermatol. 2019; 80(6): 1722–1729.e7.
  3. Maruthappu T, Taylor M. Acne and rosacea in skin of colour. Clin Exp Dermatol. 2022; 47(2): 259–263.
  4. Yang X. Relationship between Helicobacter pylori and Rosacea: review and discussion. BMC Infect Dis. 2018; 18(1): 318.
  5. Wang FY, Chi CC. Rosacea, germs, and bowels: a review on gastrointestinal comorbidities and gut-skin axis of rosacea. Adv Ther. 2021; 38(3): 1415–1424.
  6. Searle T, Ali FR, Carolides S, et al. Rosacea and the gastrointestinal system. Australas J Dermatol. 2020; 61(4): 307–311.
  7. Oge' LK, Muncie HL, Phillips-Savoy AR. Rosacea: diagnosis and treatment. Am Fam Physician. 2015; 92(3): 187–196.
  8. Zip C. The role of skin care in optimizing treatment of acne and rosacea. Skin Therapy Lett. 2017; 22(3): 5–7.
  9. Katta R, Kramer MJo. Skin and diet: an update on the role of dietary change as a treatment strategy for skin disease. Skin Therapy Lett. 2018; 23(1): 1–5.
  10. Rivero AL, Whitfeld M. An update on the treatment of rosacea. Aust Prescr. 2018; 41(1): 20–24.
  11. FitzGerald R, Smith SM. An overview of Helicobacter pylori infection. Methods Mol Biol. 2021; 2283: 1–14.
  12. Callaway E. Famous ancient iceman had familiar stomach infection. Nature. 2016.
  13. Guarneri C, Ceccarelli M, Rinaldi L, et al. Helicobacter pylori and skin disorders: a comprehensive review of the available literature. Eur Rev Med Pharmacol Sci. 2020; 24(23): 12267–12287.
  14. de Brito BB, da Silva FA, Soares AS, et al. Pathogenesis and clinical management of gastric infection. World J Gastroenterol. 2019; 25(37): 5578–5589.
  15. Kunovsky L, Dite P, Jabandziev P, et al. infection and other bacteria in pancreatic cancer and autoimmune pancreatitis. World J Gastrointest Oncol. 2021; 13(8): 835–844.
  16. AlBalbeesi A, Alsalman H, Alotaibi H, et al. Prevalence of Helicobacter pylori infection among rosacea and chronic spontaneous urticaria patients in a tertiary hospital in Riyadh, Saudi Arabia. Cureus. 2021; 13(8): e17617.
  17. Kim HS. Microbiota in rosacea. Am J Clin Dermatol. 2020; 21(Suppl 1): 25–35.
  18. Daniluk J. Helicobacter pylori eradication – the most common mistake. Lekarz POZ. 2021; 7(6): 411–420.
  19. Szlachcic A, Szlachcic A, Sliwowski Z, et al. Helicobacter pylori and its eradication in rosacea. J Physiol Pharmacol. 1999; 50(5): 777–786.
  20. Adriani A, Saracco GM, Pellicano R. Helicobacter pylori infection and dermatologic diseases: time to turn the page? G Ital Dermatol Venereol. 2020; 155(6): 709–710.
  21. Saleh P, Naghavi-Behzad M, Herizchi H, et al. Effects of Helicobacter pylori treatment on rosacea: a single-arm clinical trial study. J Dermatol. 2017; 44(9): 1033–1037.
  22. Authors, Responsible in representation of the DGVS:. S2k-Guideline Helicobacter pylori and gastroduodenal ulcer disease. Z Gastroenterol. 2017; 55(2): 167–206.
  23. Woo YuRi, Han YuJ, Kim HS, et al. Updates on the risk of neuropsychiatric and gastrointestinal comorbidities in rosacea and its possible relationship with the gut-brain-skin axis. Int J Mol Sci. 2020; 21(22).
  24. Sinha S, Lin G, Ferenczi K. The skin microbiome and the gut-skin axis. Clin Dermatol. 2021; 39(5): 829–839.
  25. De Pessemier B, Grine L, Debaere M, et al. Gut-Skin axis: current knowledge of the interrelationship between microbial dysbiosis and skin conditions. Microorganisms. 2021; 9(2): 353.
  26. Tutka K, Żychowska M, Reich A. Diversity and composition of the skin, blood and gut microbiome in rosacea-a systematic review of the literature. Microorganisms. 2020; 8(11): 1756.
  27. Nam JH, Yun Y, Kim HS, et al. Rosacea and its association with enteral microbiota in Korean females. Exp Dermatol. 2018; 27(1): 37–42.
  28. Chen YJ, Lee WH, Ho HJ, et al. An altered fecal microbial profiling in rosacea patients compared to matched controls. J Formos Med Assoc. 2021; 120(1 Pt 1): 256–264.
  29. Su HJ, Chiu YT, Chiu CT, et al. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019; 118(7): 1083–1092.
  30. Weimers P, Munkholm P. The natural history of IBD: lessons learned. Curr Treat Options Gastroenterol. 2018; 16(1): 101–111.
  31. Daou H, Paradiso M, Hennessy K, et al. Rosacea and the microbiome: a systematic review. Dermatol Ther (Heidelb). 2021; 11(1): 1–12.
  32. Egeberg A, Weinstock LB, Thyssen EP, et al. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017; 176(1): 100–106.
  33. Kim M, Choi KH, Hwang SeW, et al. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: A population-based cross-sectional study. J Am Acad Dermatol. 2017; 76(1): 40–48.
  34. Margolis KG, Cryan JF, Mayer EA. The microbiota-gut-brain axis: from motility to mood. Gastroenterology. 2021; 160(5): 1486–1501.
  35. Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. Curr Gastroenterol Rep. 2016; 18(2): 8.
  36. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30(6): 492–506.
  37. Maarouf M, Platto JF, Shi VY. The role of nutrition in inflammatory pilosebaceous disorders: Implication of the skin-gut axis. Australas J Dermatol. 2019; 60(2): e90–e98.
  38. Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008; 6(7): 759–764.
  39. Mearin F, Lacy BE, Chang L. Bowel disorders. Gastroenterology. 2016; 18: S0016-5085(16)00222-5.
  40. Spiegel B. Gravity and the gut: a hypothesis of irritable bowel syndrome. Am J Gastroenterol. 2022; 117(12): 1933–1947.
  41. Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil. 2011; 17(4): 349–359.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl